α,β-Methylene ATP trisodium
CAS No. 1343364-54-4
α,β-Methylene ATP trisodium( —— )
Catalog No. M33198 CAS No. 1343364-54-4
α,β-Methylene ATP trisodium, a phosphonate analog of ATP, is a selective P2X agonist that induces enhanced contraction of UBSM. α,β-Methylene ATP trisodium inhibits P2X1 and P2X3, but is inactive against P2X2, 4 and 7.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 1518 | In Stock |
|
| 50MG | 1978 | In Stock |
|
| 100MG | 3132 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Nameα,β-Methylene ATP trisodium
-
NoteResearch use only, not for human use.
-
Brief Descriptionα,β-Methylene ATP trisodium, a phosphonate analog of ATP, is a selective P2X agonist that induces enhanced contraction of UBSM. α,β-Methylene ATP trisodium inhibits P2X1 and P2X3, but is inactive against P2X2, 4 and 7.
-
Descriptionα,β-Methylene-ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene-ATP trisodium is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetP2X Receptor
-
RecptorP2X Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1343364-54-4
-
Formula Weight571.15
-
Molecular FormulaC11H15N5Na3O12P3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 125 mg/mL (218.86 mM; Ultrasonic)
-
SMILESO[C@H]1[C@@H](O[C@@H]([C@H]1O)COP(CP(OP([O-])(O)=O)([O-])=O)([O-])=O)N2C3=NC=NC(N)=C3N=C2.[Na+].[Na+].[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
GSK-1482160
GSK-1482160 is a CNS-penetrant negative allosteric modulator of P2X7 receptor with oral activity.
-
Opiranserin hydrochl...
Opiranserin (VVZ-149) hydrochloride is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. It shows antagonistic activity on rP2X3 (IC50=0.87 μM). It is development as an injectable agent for the treatment of postoperative pain.
-
JNJ-55308942
JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4; also shows insignificant inhibition of nine CYP isoforms (IC50>15 uM).
Cart
sales@molnova.com